Precision Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics, Therapies), By Applications (Oncology, Neurosciences, Immunology, Respiratory, Others), By End Use, By Region, and Segment Forecasts - 2035

Precision Medicine Market Overview

precision medicine market Size was estimated at 142992.76 USD million in 2025, The industry is projected to grow from 156720.06 USD million in 2026 to 206327.1 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 9.6% during the forecast period 2026 - 2035.

The Precision Medicine Market is expanding as genomic sequencing, molecular diagnostics, companion diagnostics, targeted therapies, liquid biopsy, artificial intelligence, digital pathology, and biomarker-guided drug development become more deeply integrated into routine healthcare. Diagnostics account for an estimated 57% of current market activity, while Therapies represent approximately 43%. Oncology is the dominant application with approximately 48% market share, followed by Immunology at 17%, Neurosciences at 13%, Respiratory at 9%, and Others at 13%. Precision medicine increasingly combines DNA, RNA, protein, imaging, clinical-history, and lifestyle information to identify patient subgroups that are more likely to respond to specific treatments. Modern comprehensive genomic profiling can assess hundreds of cancer-related genes in a single workflow, while whole-genome sequencing evaluates approximately 3 billion DNA base pairs. The movement from one-marker testing toward broad molecular profiling is improving identification of actionable alterations, supporting targeted treatment selection and helping clinical development programs enroll biologically defined patient populations.

The United States represents the largest national Precision Medicine Market environment because it combines extensive genomic testing, biopharmaceutical research, targeted drug development, clinical trials, oncology networks, diagnostic laboratories, sequencing infrastructure, and artificial-intelligence investment. North America is estimated to account for approximately 43% of global activity, with the United States representing more than 85% of regional demand. Johnson & Johnson, LabCorp, Abbott Laboratories, and Illumina provide direct U.S. representation among the supplied companies. Precision oncology is particularly important because comprehensive genomic profiling increasingly guides treatment for patients with advanced cancers, although adoption gaps remain. Fewer than approximately 50% of patients with metastatic non-small cell lung cancer currently receive next-generation sequencing in some care settings despite extensive actionable biomarker availability. Expanding distributed diagnostic systems and payer coverage therefore represent significant opportunities to bring molecular testing closer to community hospitals and regional oncology centers.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Diagnostics are expected to hold approximately 57% market share as genomic profiling, companion diagnostics, liquid biopsy, molecular pathology, and sequencing increasingly guide patient selection before targeted treatment begins.
• Leading Application: Oncology is projected to dominate with approximately 48% market share because molecularly targeted drugs, immunotherapies, companion diagnostics, genomic profiling, and residual-disease monitoring are increasingly embedded across cancer care.
• Leading Region: North America is estimated to account for approximately 43% of global activity, supported by advanced clinical genomics, biotechnology investment, companion diagnostics, targeted therapies, and extensive U.S. laboratory infrastructure.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 12.1% annually as genomic laboratories, oncology programs, biopharmaceutical development, sequencing capacity, and precision diagnostic infrastructure increase across major economies.
• Technology Trend: Whole-genome sequencing is advancing rapidly, with modern platforms analyzing approximately 3 billion human DNA base pairs and enabling increasingly comprehensive disease characterization and biomarker discovery.
• Market Driver: Biomarker-guided cancer care remains the strongest growth catalyst, while fewer than approximately 50% of metastatic non-small cell lung cancer patients receive comprehensive next-generation sequencing in some current care settings.
• Competitive Landscape: Companion diagnostic collaboration is accelerating, with one leading diagnostics supplier maintaining partnerships with more than 85 pharmaceutical companies to develop predictive tests for precision treatment selection.
• Future Outlook: Molecular residual disease testing will expand strongly through 2035 as ultra-sensitive workflows increasingly combine whole-genome sequencing with digital PCR to track treatment response and cancer recurrence.

Latest Trends

Artificial intelligence is becoming one of the most influential trends in the Precision Medicine Market because algorithms can extract treatment-relevant information from pathology images, molecular data, genomic sequences, clinical records, and patient histories at scales that exceed manual analysis. In April 2025, the first computational pathology companion diagnostic to receive U.S. Breakthrough Device Designation demonstrated how artificial intelligence can be combined with immunohistochemistry to identify patients for targeted cancer treatment. Such systems can evaluate individual cells across entire tumor images rather than relying solely on conventional manual scoring. Oncology, which represents approximately 48% of current precision medicine activity, is likely to benefit most because biomarker expression can vary significantly across tumor regions. AI-enabled pathology can standardize scoring, reduce inter-observer variability, support pharmaceutical clinical trials, and potentially detect therapeutic subgroups that traditional interpretation may miss.

Distributed genomic testing is another major trend. Historically, comprehensive molecular profiling was concentrated in a limited number of centralized laboratories, requiring specimens to travel long distances and potentially adding several days to diagnostic turnaround. During 2025 and 2026, major sequencing and laboratory companies expanded distributed tissue and liquid-biopsy testing strategies designed for hospitals and community health systems. Current next-generation sequencing systems can evaluate hundreds of genomic variants simultaneously, while emerging whole-genome approaches expand analysis beyond targeted panels. Molecular residual disease testing is also evolving from narrow mutation panels toward broader whole-genome strategies that can identify tumor-derived signals after treatment. These developments support precision medicine across the full cancer pathway, including diagnosis, therapy selection, response monitoring, recurrence detection, and clinical-trial matching.

Market Dynamics

Driver

""Biomarker-guided therapies are transforming clinical treatment selection.""

The increasing availability of targeted therapies is the strongest structural driver of the Precision Medicine Market. Oncology accounts for approximately 48% of market activity because many cancers are now classified not only by organ location but also by molecular characteristics such as EGFR, HER2, BRAF, ALK, MET, KRAS, BRCA, IDH, PD-L1, and mismatch-repair status. A lung cancer patient can now be tested for more than 10 clinically relevant biomarkers before treatment selection, compared with the far more limited molecular testing available 2 decades ago. Companion diagnostics link specific biomarkers with particular therapies, helping physicians identify patients more likely to benefit while avoiding ineffective treatment in biomarker-negative populations. This approach also improves clinical-trial efficiency by enriching study populations according to disease biology.

The development of comprehensive genomic profiling provides another major driver because next-generation sequencing allows laboratories to analyze many genes simultaneously rather than ordering sequential single-gene tests. Sequential testing can exhaust small biopsy specimens and delay treatment, whereas broad NGS panels can evaluate hundreds of genomic regions through a single workflow. Fewer than approximately 50% of metastatic non-small cell lung cancer patients receive NGS in some care settings despite widespread guideline support for comprehensive profiling in advanced disease. Closing this adoption gap could increase diagnostic demand substantially without requiring a proportional increase in cancer incidence. Diagnostics already represent approximately 57% of market activity, reflecting their central role in determining which patients should receive increasingly specialized therapies.

Restraint

""Testing complexity and unequal access continue to restrict precision medicine adoption.""

Unequal access to advanced molecular testing remains an important restraint because sequencing, pathology, laboratory infrastructure, specialist interpretation, and reimbursement vary significantly between healthcare systems. Comprehensive genomic profiling may involve hundreds of genes and generate thousands of genomic observations, but only a smaller subset is currently actionable in routine care. Community hospitals can lack molecular tumor boards or bioinformatics specialists needed to interpret complex findings. Turnaround time also matters because patients with aggressive cancers may need treatment within 1 to 2 weeks. Sending specimens to distant centralized laboratories can add logistical delay, while small biopsies sometimes contain insufficient tumor material for complete testing. These constraints explain why NGS adoption remains below approximately 50% in some advanced lung cancer populations.

Data complexity creates another restraint. A whole human genome contains approximately 3 billion base pairs, producing far more information than a targeted panel evaluating several hundred genes. Storage, analysis, annotation, consent, cybersecurity, and clinical interpretation become increasingly difficult as precision medicine expands from targeted sequencing toward whole-genome, transcriptomic, proteomic, and imaging information. Laboratories must distinguish pathogenic variants from benign differences, and interpretations can change as new evidence emerges. A genomic variant classified as uncertain in 2025 may become clinically actionable several years later, creating the need for reanalysis capabilities. Healthcare systems therefore require sustainable informatics infrastructure rather than viewing sequencing solely as a laboratory assay.

Opportunity

""Liquid biopsy and residual-disease monitoring create major new precision medicine opportunities.""

Liquid biopsy provides one of the largest opportunities because tumor-derived DNA can be analyzed from blood when tissue is unavailable, difficult to obtain, or unsuitable for repeated monitoring. Tissue biopsies typically provide a single snapshot of a tumor, whereas blood collection can potentially be repeated several times during treatment. In March 2026, distributed tissue and liquid-biopsy testing expanded through collaboration between major sequencing and laboratory providers, including comprehensive genomic profiling and whole-genome sequencing development. This approach can extend advanced molecular testing beyond large academic centers. Oncology's approximately 48% market share gives liquid biopsy a substantial addressable base across lung, colorectal, breast, prostate, and other cancers.

Molecular residual disease represents another major opportunity. After surgery or systemic treatment, imaging may show no visible cancer even when microscopic disease remains. Highly sensitive molecular assays can potentially identify residual tumor signals much earlier than conventional recurrence detection. During 2026, new whole-genome sequencing research workflows were introduced to enable distributed MRD analysis for solid tumors and blood cancers. Another tumor-informed platform combined whole-genome sequencing with digital PCR to identify structural variants and track patient-specific disease markers. These developments shift precision medicine beyond initial treatment selection toward longitudinal monitoring. A patient could theoretically receive molecular assessment at 4 or more time points across diagnosis, treatment, remission, and surveillance, increasing testing intensity per patient.

Challenge

""Translating massive biological datasets into actionable clinical decisions remains difficult.""

Clinical interpretation represents one of the largest challenges because precision medicine generates information faster than healthcare systems can convert it into standardized treatment decisions. A comprehensive sequencing assay can reveal dozens of genomic alterations, yet only a portion may have approved therapies or guideline-supported clinical relevance. Molecular tumor boards can bring together oncologists, geneticists, pathologists, laboratory scientists, and bioinformaticians, but such expertise is not available in every hospital. Even within Oncology, which represents approximately 48% of current demand, evidence levels vary by tumor type and stage. A biomarker may predict response in 1 cancer but remain investigational in another, requiring physicians to interpret disease context rather than simply matching every mutation with a drug.

Population diversity creates a second challenge because genomic databases historically contain uneven representation across geographic and ancestral groups. Precision algorithms perform best when training datasets reflect the populations where they are deployed. Whole-genome sequencing generates approximately 3 billion base pairs per individual, but the clinical meaning of many variants remains poorly characterized in underrepresented populations. This can increase uncertain findings and reduce the accuracy of polygenic or genomic risk models. Asia-Pacific, projected to expand at approximately 12.1% annually, therefore represents both a growth opportunity and a data-development priority. Expanding regionally diverse genomic databases will be essential to improve the performance of precision medicine across broader patient populations.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Diagnostics: Diagnostics lead with approximately 57% market share and include genomic sequencing, molecular testing, companion diagnostics, liquid biopsy, immunohistochemistry, biomarker assays, pathology, and other technologies used to characterize individual disease biology. Modern comprehensive genomic profiling can examine hundreds of cancer-associated genes in a single test, while whole-genome sequencing evaluates approximately 3 billion DNA base pairs. Companion diagnostics increasingly connect biomarker results directly with therapy eligibility. Diagnostics are particularly important in Oncology because multiple actionable alterations can occur within cancers that appear similar under conventional microscopy. The segment is expanding beyond diagnosis toward treatment monitoring, recurrence detection, hereditary risk analysis, and clinical-trial selection.

Therapies: Therapies represent approximately 43% of market activity and include treatments selected according to molecular, genetic, immunological, pathological, or other patient-specific characteristics. Targeted oncology drugs can inhibit proteins produced by specific genomic alterations, while immunotherapies increasingly depend on biomarkers such as PD-L1, mismatch repair, or tumor molecular characteristics. Precision therapy is also expanding in Immunology, Neurosciences, and Respiratory disease as researchers identify biological subgroups within conditions previously treated as single disorders. Modern clinical development increasingly includes biomarker strategies from Phase 1 onward, helping companies define responder populations earlier and potentially reduce the size of later trials.

By Applications

Oncology: Oncology dominates with approximately 48% market share because cancer is genetically heterogeneous and has the largest established ecosystem of molecular diagnostics and targeted therapies. Comprehensive genomic profiling identifies actionable alterations, companion diagnostics determine treatment eligibility, and liquid biopsy can support monitoring when tissue sampling is impractical. Current companion diagnostic menus cover numerous biomarkers across lung, breast, colorectal, hematologic, and other cancers. In June 2026, a mismatch-repair companion diagnostic received expanded European approval across 5 cancer types and 6 treatment indications, illustrating the movement from single-tumor biomarkers toward broader molecular treatment frameworks.

Neurosciences: Neurosciences represent approximately 13% of demand and include neurodegenerative disorders, epilepsy, psychiatric conditions, neuromuscular disease, and genetically defined neurological syndromes. Precision medicine is particularly relevant to rare neurological disorders because genomic testing can shorten diagnostic journeys that previously lasted several years. Whole-exome and whole-genome sequencing can identify inherited variants across thousands of genes, while pharmacogenomic testing may support medication selection in selected neurological and psychiatric contexts. Biomarker development remains less mature than Oncology, but increasing genetic characterization is creating more defined patient subgroups.

Immunology: Immunology accounts for approximately 17% of market demand and includes autoimmune disease, inflammatory conditions, immunodeficiency, and biomarker-guided biologic treatment. Patients with the same clinical diagnosis can have markedly different molecular drivers, creating opportunities to use cytokines, antibodies, genetic markers, cellular profiles, and treatment-response biomarkers to select therapies. Modern biologics can target individual immune pathways instead of broadly suppressing the immune system. Precision approaches are especially important when patients have already failed 2 or more conventional therapies and clinicians need additional biological information to guide the next treatment strategy.

Respiratory: Respiratory represents approximately 9% of market demand and includes asthma, chronic respiratory disease, pulmonary fibrosis, and molecularly characterized pulmonary disorders. Severe asthma is increasingly divided into phenotypes and endotypes based on inflammatory markers and immune pathways, allowing biologic therapy to be directed toward specific patient subsets. Some respiratory treatment pathways evaluate biomarkers such as blood eosinophils or immunological characteristics before biologic selection. Precision oncology also overlaps with respiratory medicine through molecular testing of lung tumors, making respiratory care an important bridge between pulmonary diagnostics and genomics.

Others: Others account for approximately 13% of market demand and include cardiovascular disorders, rare genetic disease, infectious disease, metabolic conditions, pharmacogenomics, and other molecularly stratified clinical areas. Rare disease represents a significant genomic opportunity because individual disorders affect small populations but collectively involve thousands of genetic conditions. Whole-genome sequencing is increasingly valuable when targeted testing fails because approximately 3 billion DNA base pairs can be evaluated simultaneously. Pharmacogenomics also provides opportunities to predict how variants in drug-metabolizing enzymes influence individual medication response.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America leads the Precision Medicine Market with approximately 43% share, supported by advanced sequencing laboratories, targeted drug development, companion diagnostics, extensive oncology infrastructure, biotechnology investment, reimbursement mechanisms, and large clinical-trial networks. The United States dominates regional activity and provides supplied-company representation through Johnson & Johnson, LabCorp, Abbott Laboratories, and Illumina.

Distributed genomic testing is becoming an important regional strategy. In March 2026, major sequencing and laboratory providers expanded collaboration to increase access to tissue and liquid-biopsy testing across hospitals and community health systems. The initiative includes comprehensive genomic profiling and whole-genome sequencing development. This addresses an important adoption gap because fewer than approximately 50% of metastatic non-small cell lung cancer patients receive NGS in some settings. Increased reimbursement and distributed testing could move precision medicine beyond major academic centers.

Europe

Europe represents approximately 29% of global demand and has strong pharmaceutical development, genomic research, companion diagnostic testing, national healthcare systems, oncology networks, and academic medical centers. Roche and Novartis provide major supplied-company representation from Switzerland and maintain extensive precision medicine programs covering both diagnostics and targeted therapies.

European precision oncology expanded further in June 2026 when a mismatch-repair companion diagnostic received broader regulatory approval covering 5 cancer types and 6 indications. Such approvals demonstrate how biomarker testing can support treatment selection across multiple tumor types rather than remaining restricted to a single disease. European national genomics programs are also expanding sequencing infrastructure, while pharmaceutical companies increasingly integrate biomarkers into clinical development.

Asia-Pacific

Asia-Pacific accounts for approximately 22% of current demand and is projected to expand fastest at around 12.1% annually. China, Japan, South Korea, India, Singapore, and Australia are increasing genomic sequencing, biotechnology research, oncology infrastructure, targeted therapies, diagnostic laboratories, and population-genomics initiatives.

Regional growth is strengthened by large patient populations and increasing access to molecular oncology. Local sequencing capacity reduces dependence on international testing laboratories and can shorten turnaround from several weeks to fewer than 10 days for selected genomic assays. Asia-Pacific also provides an important opportunity to diversify genomic databases because historical precision medicine datasets have underrepresented many Asian populations. Expanded regional sequencing can therefore improve both market access and scientific accuracy.

Middle East & Africa

Middle East & Africa account for approximately 2% of current market demand but are increasing investment in genomic medicine, oncology, rare-disease diagnosis, and biotechnology. Gulf countries have launched national genome initiatives and advanced healthcare programs, while South Africa maintains established genomic and biomedical research capabilities.

Rare genetic disorders provide a notable opportunity because genomic sequencing can replace lengthy sequential testing. Whole-genome analysis of approximately 3 billion base pairs can identify variants missed by narrower assays, although interpretation and counseling infrastructure remain essential. Regional growth through 2035 will depend on laboratory investment, workforce training, payer support, population-specific genomic databases, and closer integration between sequencing laboratories and specialist clinicians.

List of Top Precision Medicine Companies

• Roche (Switzerland)
• Johnson & Johnson (U.S.)
• LabCorp (U.S.)
• Abbott Laboratories (U.S.)
• Novartis (Switzerland)
• Illumina (U.S.)

Top 2 Companies Market Share

Roche: Roche is estimated to account for approximately 18% of competitive activity among the supplied companies because it combines targeted therapies, tissue diagnostics, molecular testing, sequencing, companion diagnostics, digital pathology, and artificial intelligence within one precision medicine ecosystem. The company works with more than 85 pharmaceutical partners in companion diagnostics and expanded its AI pathology capabilities through a proposed PathAI acquisition in May 2026. Its June 2026 AXELIOS 1 sequencing platform is designed to enable same-day whole-genome sequencing in research workflows, adding another genomic capability to a portfolio already spanning immunohistochemistry, in situ hybridization, molecular diagnostics, and targeted treatment.

Illumina: Illumina is estimated to represent approximately 16% of competitive activity among the supplied companies, supported by extensive next-generation sequencing infrastructure and broad adoption of its platforms across genomic research and clinical oncology. Approximately 90% of sequencing data generated historically has been associated with Illumina technology, demonstrating its influence on genomic workflows. The company expanded oncology offerings during 2025 with comprehensive tumor profiling and additional companion diagnostic solutions, followed in 2026 by distributed whole-genome MRD research technology and an expanded collaboration with LabCorp. Together, Roche and Illumina represent an estimated 34% of competitive activity among the supplied companies.

Investment Analysis

Investment in the Precision Medicine Market is increasingly directed toward genomic sequencing, companion diagnostics, liquid biopsy, digital pathology, artificial intelligence, biomarker databases, and integrated clinical decision support. Diagnostics represent approximately 57% of current market activity, making molecular infrastructure a major capital priority. Sequencing platforms are becoming faster and more scalable, with new systems capable of completing research whole-genome workflows within the same day. Investment is also moving beyond sequencing hardware toward computational interpretation because analyzing approximately 3 billion DNA base pairs requires substantial bioinformatics capacity. Hospitals and laboratory groups increasingly need secure data storage, variant interpretation, automated reporting, and molecular decision support alongside sequencing instruments.

Precision oncology remains the strongest investment segment because Oncology accounts for approximately 48% of demand. Roche's planned PathAI acquisition announced in May 2026 illustrates strategic interest in combining digital pathology and AI-driven biomarker analysis, while Illumina and LabCorp expanded collaboration in March 2026 around distributed tissue and liquid-biopsy testing. Companies are also investing in molecular residual disease because longitudinal monitoring can generate several tests per patient instead of a single baseline profile. Asia-Pacific's projected approximately 12.1% annual growth strengthens the investment case for regional genomic laboratories, population databases, clinical-trial infrastructure, and locally relevant companion diagnostics.

New Product Development

New product development is increasingly focused on comprehensive testing that captures more biological information from smaller patient samples. Next-generation tumor profiling platforms are moving beyond single-gene assays toward multi-analyte panels capable of assessing hundreds of biomarkers simultaneously. Whole-genome approaches expand further by analyzing approximately 3 billion DNA base pairs, enabling structural variants and other genomic features to be evaluated without limiting analysis to predetermined genes. Roche launched AXELIOS 1 in June 2026 with same-day whole-genome sequencing capabilities for research workflows, while Illumina introduced a distributed whole-genome molecular residual disease research solution in May 2026. These technologies demonstrate how precision medicine is evolving from targeted sequencing toward broader genomic characterization.

AI-enabled companion diagnostics represent another major development direction. Roche's TROP2 computational pathology program received Breakthrough Device Designation in April 2025 and uses artificial intelligence to perform cell-by-cell tumor analysis for therapy selection. This approach can detect complex expression patterns that are difficult to reproduce through manual scoring. Liquid biopsy is also gaining product-development attention because blood-based testing avoids the need for repeated tissue biopsies. Future products through 2035 are expected to integrate at least 4 data classes, including genomics, pathology, clinical history, and treatment-response information, into increasingly personalized therapeutic recommendations.

Five Recent Developments

• April 2025: Roche received U.S. Breakthrough Device Designation for its first AI-driven computational pathology companion diagnostic, combining immunohistochemistry with cell-level algorithmic analysis to guide targeted treatment in non-small cell lung cancer.
• May 2025: LabCorp expanded its precision oncology portfolio with new solid-tumor and hematologic testing options while strengthening companion diagnostic development and integrated clinical-trial support across multiple biomarker technologies.
• May 2025: Illumina expanded its clinical oncology portfolio with additional comprehensive genomic profiling and companion diagnostic capabilities, increasing access to sequencing-based precision treatment selection across distributed clinical laboratories.
• March 2026: Illumina and LabCorp expanded collaboration around distributed comprehensive genomic profiling, liquid biopsy, and whole-genome sequencing to bring precision oncology testing closer to hospitals and community health systems.
• June 2026: Roche launched AXELIOS 1, a next-generation sequencing platform designed to support same-day whole-genome sequencing in research workflows and broaden future applications of genomic precision medicine.

Report Coverage

The Precision Medicine Market assessment covers current industry conditions and the 2026-2035 forecast period across both supplied product types and all 5 supplied applications. Product analysis includes Diagnostics at approximately 57% market share and Therapies at 43%. Application coverage includes Oncology at approximately 48%, Neurosciences at 13%, Immunology at 17%, Respiratory at 9%, and Others at 13%. Regional analysis covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with North America estimated to hold approximately 43% of current activity and Asia-Pacific projected to expand at around 12.1% annually. Technical coverage includes genomic sequencing, companion diagnostics, biomarker testing, liquid biopsy, molecular residual disease, immunohistochemistry, whole-genome sequencing, computational pathology, artificial intelligence, targeted therapies, and clinical decision support.

The competitive assessment covers the 6 supplied companies: Roche, Johnson & Johnson, LabCorp, Abbott Laboratories, Novartis, and Illumina. Analysis evaluates Diagnostics and Therapies capabilities across Oncology, Neurosciences, Immunology, Respiratory, and Others, with attention to sequencing platforms, biomarker strategies, companion diagnostics, targeted therapeutics, laboratory networks, digital pathology, and artificial intelligence. Current market technologies include sequencing of approximately 3 billion DNA base pairs, broad profiling across hundreds of cancer-related genes, AI-enabled cell-by-cell pathology analysis, distributed tissue and liquid-biopsy testing, and companion diagnostic collaborations involving more than 85 pharmaceutical partners at one leading supplier. The assessment evaluates how genomics, molecular diagnostics, targeted therapies, clinical evidence, reimbursement, AI, and decentralized testing are reshaping the Precision Medicine Market through 2035.